Trials / Completed
CompletedNCT06816264
A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Oral HRS-5346 in Adult Patients at High Risk of Cardiovascular Events With Elevated Lipoprotein(a)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of HRS-5346 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-5346 | HRS-5346 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2025-02-18
- Primary completion
- 2025-09-29
- Completion
- 2025-09-29
- First posted
- 2025-02-10
- Last updated
- 2025-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06816264. Inclusion in this directory is not an endorsement.